Initial Efficacy Data for GlycoMimetics' GMI-1271 Combined with Chemotherapy in Patients with AML to Be Presented at European Hematology Association 21st Congress
The poster (P191), entitled "Results of a Phase 1 study of GMI-1271, a
novel E-selectin antagonist in combination with induction chemotherapy
in relapse/refractory AML: a novel, well-tolerated regimen with a high
remission rate," is scheduled for
The abstract is available here
About GMI-1271
GMI-1271 is designed to block E-selectin (an adhesion molecule on cells
in the bone marrow) from binding with acute myeloid leukemia (AML) cells
in ways that help the cancer cells evade the effects of chemotherapy
treatment. Preclinical research points to the drug's potential role in
moving cancerous cells out of the protective environment of the bone
marrow where they hide and escape the effects of chemotherapy. By
blocking E-selectin, GMI-1271 also may protect normal blood-producing
cells, and reduce the toxic side effects of chemotherapy such as low
white blood cell counts that make some patients more prone to
infections. GMI-1271 may also reduce mucositis (inflammation or lesions
in the intestinal tract and mouth), which can be a side effect of
chemotherapy.
About
GlycoMimetics is a clinical-stage biotechnology company focused on
sickle cell disease and cancer.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160519005851/en/
Investor Contact:
sannes@annesassociates.com
or
Media
Contact:
jamielacey@presscommpr.com
Source:
News Provided by Acquire Media